Answer
The estimated annual risk of venous thromboembolism with NuvaRing is about 6–12 cases per 10,000 women, although individual risk may be far higher depending on underlying risk factors.
Sources for this answer
- NuvaringOrganon Pharma (UK) Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 22Document updated
Sources checked